<DOC>
	<DOCNO>NCT02640209</DOCNO>
	<brief_summary>Open-label pilot study determine safety efficacy CART-19 cell combination ibrutinib . The target dose 1-5x10xE8 CART-19 transduce cell administer via split dosing : 10 % Day 1 , 30 % Day 2 , 60 % Day 3 . 15 evaluable subject ( adult ) relapse refractory CLL/SLL achieve partial response stable disease ibrutinib therapy eligible receive CART-19 therapy .</brief_summary>
	<brief_title>Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor ( CART19 ) In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia ( CLL ) Or Small Lymphocytic Lymphoma ( SLL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Documented CD19+ CLL SLL Successful test expansion cell ( described Section 6.1 ) Patients must fail least 1 prior regimen Ibrutinib ( include single agent rituximab single agent corticosteroid ) . Note : Any relapse prior autologous SCT make patient eligible regardless prior therapy . Patients must currently receive ibrutinib least 6 month prior enrollment study : 1 . Not experience ≥ grade 2 nonhematologic ibrutinibrelated toxicity 2 . The best response ibrutinib therapy must exceed partial response stable disease ( i.e . CR CRi ) 3 . Note : Patients carry deletion chromosome 17p ( i.e . del [ 17p ] ) , and/or TP53 , BTK , PLCγ2 locus mutation , eligible receive frontline therapy ibrutinib . ECOG Performance status 0 1 18 year age old Adequate organ system function include : 1 . Creatinine &lt; 1.6 mg/dl 2 . ALT/AST &lt; 3x upper limit normal 3 . Total Bilirubin &lt; 2.0 mg/dl exception patient Gilbert syndrome ; patient Gilbert syndrome may include total bilirubin ≥ 3.0 x ULN direct bilirubin ≤ 1.5 x ULN . Patients relapse disease prior allogeneic SCT ( myeloablative nonmyeloablative ) eligible meet inclusion criterion : 1 . Have active GVHD require immunosuppression 2 . Are 6 month transplant No contraindication leukapheresis Left Ventricular Ejection fraction &gt; 40 % Gives voluntary inform consent Subjects reproductive potential must agree use acceptable birth control method . CLL patient know suspect transformed disease ( i.e . Richter 's transformation ) . Note : biopsy proven absence transformation require . Pregnant lactating woman . The safety therapy unborn child know . Female study participant reproductive potential must negative serum urine pregnancy test perform within 48 hour infusion . Uncontrolled active infection . Active hepatitis B hepatitis C infection . Concurrent use systemic steroid chronic use immunosuppressant medication . Recent current use inhale steroid exclusionary . Any uncontrolled active medical disorder would preclude participation outline . HIV infection . Patients active CNS involvement malignancy . Patients prior CNS disease effectively treat eligible provide treatment &gt; 4 week enrollment . Class III/IV cardiovascular disability accord New York Heart Association Classification . Subjects clinically apparent arrhythmia arrhythmia stable medical management within two week enrollment . Patients known history prior diagnosis optic neuritis immunologic inflammatory disease affect central nervous system .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>